>> and just for fun <<
sheesh!
not in the mood for that...... have had to work far too hard for mediocre (relative to most here, not relative to investors in general) return during this rally.
major sexy project to immunologists.......
Generex Announces a Cancer Research Collaboration with Transgene on Ii Suppression Technology
Wednesday October 15, 9:54 am ET
TORONTO, Oct. 15 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation's (Nasdaq: GNBT - News) Antigen Express subsidiary today announced a research collaboration with Transgene S.A., Strasbourg, France (Nasdaq: TRGNY - Nouveau Marche: TRANSGENE or FR0005175080) to assess the Ii suppression technology in preclinical cancer models.
ADVERTISEMENT
Transgene will insert Antigen Express Ii suppression gene in its adenovirus based cancer immunotherapy products and evaluate the constructs in several animal models. The program is expected to proceed for up to 12 months after which time the companies have agreed to review the data in the view of further collaboration.
Robert E. Humphreys, MD, PhD, founder of Antigen Express, said, "Transgene has recognized expertise in the molecular biology of gene delivery and expression, as well as in the evaluation of immunologic approaches to the treatment of cancer."
This approach to the treatment of cancer involves converting cancer cells in vivo into antigen presenting cells capable of inducing a potent anti-tumor CD4+ T-helper cell immune response. For an improved anti cancer immune response, it combines (1) the enhancement of antigen presentation via the Ii suppression technology and (2) the local expression of immunostimulatory cytokines generated by Transgene products. In addition, the technology is also being used in the development of DNA vaccines for HIV and other diseases.
About Generex
Generex acquired Antigen Express in August 2003. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. Generex is engaged in the research and development of drug delivery systems and technology. To date, it has focused on developing a platform technology for the buccal delivery -- delivery to the oral cavity for absorption through the inner mouth mucosa -- of drugs that historically have been administered only by injection. Generex's buccal delivery technology has application to a large number of drugs and vaccines.
This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation. |
